Case Study

Developing a Global Advocacy
Network Strategy for a Rare

Background and Objectives

A global biopharmaceutical company wanted to identify and map advocacy stakeholders to activities, areas of interest, and spheres of influence as an input to a global advocacy strategy for a rare neurodegenerative disease in 8 countries of interest (US, Canada, UK, Spain, Italy, France, China and Japan)

Approach and Recommendations (Methodology)

SmartAnalyst adopted a three-phased approach to identify the advocacy landscape for rare diseases, including the evolving policies and trends

Phase I: Map the Advocacy Landscape for a Rare Neurodegenerative Disease

  • Conducted secondary research and identified all relevant rare disease groups (organizations with focus on broad neurologic disorders, with special interest in rare neurodegenerative diseases, organizations focused only on the disease of interest, and research/ scientific consortiums)
    • Provided a brief description of their partnerships, networks, and geographic reach
    • Identified gaps in current advocacy landscape
  • Shortlisted 12 key advocacy groups based on their international recognition, local operations, role in clinical development, patient access programs, and awareness generation
  • Provided an overview of relevant scientific consortiums and key advocacy meetings

Phase II: Profile Key Relevant Rare Neurodegenerative Disease Advocacy Organizations

  • Created detailed profiles of relevant, shortlisted advocacy organizations; these profiles included information on leadership/contacts, strategic imperatives/interests, mission, policy priorities and their key projects, annual budget/financials, sources of support/sponsorship/funding and partnerships

Phase III: Identify Trends and Implications in Rare Neurodegenerative Disease Advocacy and Policy

  • Covered advocacy trends, policy initiatives that could impact patients, research and funding trends, emerging partnership models, and comparative situation across countries and regions
  • Identified aspects that required strengthening/support (at the country or regional level) and inferred their potential impact/implications for the client
  • Identified areas and opportunities that matched the client’s objectives

Time Frame

7 weeks


  • Identified advocacy groups that could be considered for partnering to foster client’s advocacy, policy, and research activities
  • Identified relevant trends in advocacy and policy and potential areas of opportunity

About SmartAnalyst: Driving pipeline and portfolio value for global biopharma and life science companies

SmartAnalyst helps biopharma companies make key decisions at the Disease, Asset, and Portfolio levels, utilizing our proprietary strategic frameworks.

We provide comprehensive, integrated solutions based on our deep understanding of the science, the market, and the key business decisions that our clients face. We deploy agile, cross-functional project teams that are responsive to client needs.